From Startup Precision Biosciences Link to Full Article: http://precisionbiosciences.com/precision-biosciences-and-durham-stem-students-lead-launch-of-first-genome-editing-experiment-into-space/ CAPE CANAVERAL, FL, USA, December 6th, 2018 – Precision BioSciences today announced that the world’s first genome editing experiment in space has been launched aboard a SpaceX Dragon cargo spacecraft on a Falcon 9 rocket. The mission was launched from Cape
From Startup Neon Therapeutics Link to Full Article: CAMBRIDGE, Mass. and SAN CARLOS, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, and Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that patient dosing has begun in NT-003, Neon’s Phase 1b
From Startup Dermavant Link to Full Article: https://dermavant.com/dermavant-sciences-to-present-new-data-on-cerdulatinib-for-atopic-dermatitis-and-vitiligo-at-the-3rd-annual-inflammatory-skin-disease-summit/ December 6, 2018 BASEL, Switzerland—Dec. 6, 2018—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria.
From Startup Axovant Link to Full Article: http://investors.axovant.com/news-releases/news-release-details/axovant-announces-feedback-fda-meeting-regarding-axo-lenti-pd Meeting with FDA confirmed that studies previously conducted using first generation ProSavin® may be considered part of a single development program with AXO-Lenti-PD Confirmed with FDA that the proposed current manufacturing process and quality control testing is adequate for the clinical program
From Startup Eidos Therapeutics Link to Full Article: http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-appoints-william-lis-board-directors SAN FRANCISCO, Dec. 06, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large unmet need in transthyretin (TTR) amyloidosis (ATTR), today announced the appointment of William Lis, to Eidos’ Board of Directors,